Apovincaminic acid
Based on 1 publication(s) in Google Scholar
Apovincaminic acid is the major metabolite of Vinpocetine (HY-13295), with blood-brain barrier permeability and oral activity. Apovincaminic acid is detectable in the plasma of pregnant rabbits after oral administration of Vinpocetine. Apovincaminic acid is absorbable from all segments of the gastrointestinal tract of Norway rat, with the stomach as the primary absorption site, and is excreted via urine and feces. Apovincaminic acid is used in the research of cerebrovascular diseases.
For research use only. We do not sell to patients.
- CAS No.: 27773-65-5
- Formula: C20H22N2O2
- Molecular Weight:322.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Apovincaminic acid
More
Biological Activity
Apovincaminic acid is the major metabolite of Vinpocetine (HY-13295), a vinca alkaloid derivative that blocks Na+ channels. Vinpocetine inhibits IKK with an IC50 value of 17.17 μM. Vinpocetine also acts as a PDE inhibitor and suppresses NF-κB-dependent inflammatory responses by directly targeting IKK[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Apovincaminic acid (0.148 μCi, 10 mg/kg; direct injection into ligated gastrointestinal segments, i.v., p.o.; 1 hour, 72 hours) is absorbed from all tested segments of the Rattus norvegicus gastrointestinal tract (with notable uptake in stomach and jejunum walls), with approximately 50% of an oral dose absorbed, and is excreted primarily in urine after i.v. administration and in faeces after oral administration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:RG-Wistar (male, 180-210 g)[2]
-
Dosage:0.148 μCi (in situ study); 10 mg/kg (excretion study)
-
Administration:direct injection into ligated gastrointestinal segments; 1 hour (in situ study); i.v., p.o.; 72 hours (excretion study)
-
Result:Absorbed Apovincaminic acid from all tested gastrointestinal segments.
Retained most drug dose in stomach, duodenum and jejunum lumen and wall 1 h after oral intake.
Recovered total 79.26% radioactive substance in urine and feces within 72 h post intravenous injection.
Recovered total 80.19% radioactive substance in urine and feces within 72 h post oral administration.
Revealed about 50% absorption rate for oral dosage form.
Detected original apovincaminic acid in urine under both administration modes.
Chemical Information
-
CAS No. 27773-65-5
-
Molecular Weight 322.41
-
Formula C20H22N2O2
-
SMILES
C(C)[C@]12[C@]3(C=4N(C=5C(C4CCN3CCC1)=CC=CC5)C(C(O)=O)=C2)[H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Birth Defects Res
Developmental Toxicity Evaluation of the Dietary Supplement Vinpocetine Using Mouse and Human 3D Gastruloids. [Abstract]2026 May;118(5):e70060. PMID: 42167926
Purity & Documentation
References
[1]. Catlin N, et al. Embryo-fetal development studies with the dietary supplement vinpocetine in the rat and rabbit. Birth defects research. 2018 Jun 01;110(10):883-896. [Content Brief]
[2]. Pudleiner P, et al. Study on the absorption of vinpocetine and apovincaminic acid. European journal of drug metabolism and pharmacokinetics. 1993;18(4):317-21. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Apovincaminic acid Related Classifications
HY-133813 Related Classifications
Powered by Bioz